Save up -80% on Ustekinumab
Note: this is a drug discount program, not an insurance plan.
2018 Price of Ustekinumab
* price without discount in nearest pharmacy. Price may vary.
We offer free Ustekinumab coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your discount card in most local pharmacies to get a discount on Ustekinumab every time. What are you waiting for? Claim your prescription drug card now!
Discount Cards 16,000+
Clients Benefit 29%
Total savings $4,735,080
What is Ustekinumab
Ustekinumab, is a human immunosuppressive drug developed by the biotechnology company Centocor. It is a laboratory-manufactured, monoclonal antibody directed against interleukins IL-12 and IL-23. Since 2009, ustekinumab has been approved in US, Canada, and Europe for the treatment of plaque psoriasis and psoriatic arthritis. In September 2016, Janssen announced that the FDA approved the medication for the treatment of moderate-severe Crohn’s disease.
Ustekinumab mechanism of action
Ustekinumab is a human IgG1-kappa monoclonal antibody designed to interfere with the triggering of the body’s inflammatory response through the suppression of certain cytokines. Specifically, ustekinumab blocks interleukin IL-12 and IL-23 by binding with high affinity and specificity to the p40 subunit of IL-12 and IL-23, therefore disrupting the proinflammatory pathway that contributes to several chronic diseases. In a more minor role, ustekinumab also interferes with the expression of monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor-alpha (TNF- ), interferon-inducible protein-10 (IP-10), and interleukin IL-8.
Dosage forms of Ustekinumab
|Injection, solution||subcutaneous||45 mg/.5mL|
|Injection, solution||subcutaneous||90 mg/mL|
Humans and other mammals
Indication of Ustekinumab
Ustekinumab is indicated for management of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy; or is used alone or in conjunction with methotrexate for the management of active psoriatic arthritis in adults. The FDA approved the use of ustekinumab in September 2016 for the treatment of moderate to severe Crohn’s disease. The use of ustekinumab may improve short term clinical response but not clinical remission in moderate to severe Crohn’s disease.
Toxicity of Ustekinumab
RX24 Drugs Disclaimer: before buying a Ustekinumab on prescription, consult your healthcare provider. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.